Shrink Nanotechnologies, Inc. announced that their scientific founder, Dr. Michelle Khine, has received a multi-year and multi-million dollar grant from the National Institutes of Health (NIH) to work on her shrink-film based diagnostic platforms. Additionally, she was given the NIH Director’s New Innovator Award.
The core of the technology underlying this grant is undergoing commercialization by Shrink Nanotechnologies in the form of their NanoShrink branded shrink films, StemDisc cell culturing devices and many additional products that are under development using this innovative shrink-film based platform. The Company’s initial suites of products are slated for commercial sale later this year.
The grant to Dr. Khine is $2.295 million over five years. The grant will fund the research and development of “Shrink-Induced Manufacturing Platforms for Low-Cost Diagnostics (SIMPL-CD),” which aims to develop Khine’s existing micro- and nanofabrication technology to create microfluidic devices to detect rotavirus infections from saliva samples in children in developing countries.
Mark L. Baum, Shrink’s Founder and CEO stated, “NIH’s recognition of the intelligence, creativity and promise behind Dr. Khine’s work, along with MIT’s Technology Review Magazine’s TR 35 Award which Dr. Khine received last year, is more important recognition of Dr. Khine’s important work and the platform that we are working on commercializing. It is also another step forward in the growing momentum behind working with low cost, flexible and simple design platforms such as our NanoShrink platform, which was designed by and which is utilized in Dr. Khine’s lab. This award will go a long way towards fueling new innovation based on the NanoShrink platform and towards making Dr. Khine’s goal of building and commercializing low cost and flexible diagnostic tools, which have specific application for diseases that typically affect young and poor children, a reality.”
Headquartered in Carlsbad, California, Shrink Nanotechnologies, Inc. is a nanotechnology company developing products and licensing opportunities in the solar energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses. The Company is a one-of-a-kind FIGA™ organization, which focuses on leveraging contributions from experts in Finance, Industry, Government and Academia. Shrink owns and develops proprietary and patent-pending nano-sized technologies, components and product systems. Their NanoShrink™ material is a pre-stressed polymer which is used in a patent pending manufacturing platform with numerous applications.
For more information visit: www.shrinknano.com
Let us hear your thoughts below: